75 patents
Page 3 of 4
Utility
Varicella zoster virus (VZV) vaccine
29 Jun 21
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella
Filed: 15 Mar 18
Utility
Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
8 Jun 21
The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.
Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty
Filed: 11 Jul 14
Utility
Infectious disease vaccines
18 May 21
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tai Zaks, Sunny Himansu
Filed: 21 Jul 16
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
11 May 21
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 7 Apr 20
Utility
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
11 May 21
The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
Filed: 18 May 17
Utility
Methods of using OX40 ligand encoding polynucleotides
11 May 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. Frederick, Ailin Bai
Filed: 16 Aug 19
Utility
Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
4 May 21
The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
Filed: 18 May 17
Utility
MRNA combination therapy for the treatment of cancer
13 Apr 21
The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer.
Joshua P. Frederick, Susannah Hewitt, Ailin Bai, Stephen G. Hoge, Vladimir Presnyak, Iain McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 28 Jun 19
Utility
Betacoronavirus mRNA vaccine
2 Mar 21
The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu
Filed: 21 May 20
Utility
Terminally Modified RNA
23 Feb 21
The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
Tirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin De Fougerolles, Noubar B. Afeyan
Filed: 5 Oct 18
Utility
Influenza vaccine
23 Feb 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Giuseppe Ciaramella
Filed: 10 Nov 17
Utility
Delivery and formulation of engineered nucleic acids
26 Jan 21
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression.
Antonin de Fougerolles, Sayda M. Elbashir
Filed: 21 Mar 18
Utility
Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides
4 Jan 21
The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator.
Eric Yi-Chun Huang, Sze-Wah Tse, Jared Iacovelli, Kristine McKinney, Nicholas Valiante
Filed: 18 Feb 19
Utility
Removal of DNA fragments in mRNA production process
7 Dec 20
The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process.
William Joseph Issa, Yuxun Wang, Stephane Bancel
Filed: 29 Jul 18
Utility
Compounds and compositions for intracellular delivery of therapeutic agents
7 Dec 20
The disclosure features novel lipids and compositions involving the same.
Kerry E. Benenato, Ellalahewage Sathyajith Kumarasinghe, Mark Cornebise
Filed: 11 Apr 19
Utility
Methods for therapeutic administration of messenger ribonucleic acid drugs
30 Nov 20
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen Hoge, Tirtha Chakraborty, Gilles Besin, Ruchi Jain
Filed: 4 Oct 16
Utility
Polynucleotides encoding immune modulating polypeptides
26 Oct 20
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
Joseph Beene Bolen, Joshua P. Frederick
Filed: 14 Jun 18
Utility
Compounds and compositions for intracellular delivery of agents
12 Oct 20
The disclosure features amino lipids and compositions involving the same.
Kerry E. Benenato, William Butcher
Filed: 21 Dec 16
Utility
Modified Polynucleotides for the production of biologics and proteins associated with human disease
14 Sep 20
The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide.
Stephane Bancel, Tirtha Chakraborty, Antonin De Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
Filed: 22 Oct 17
Utility
Engineered nucleic acids and methods of use thereof
24 Aug 20
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms.
Stephane Bancel, Jason P. Schrum, Alexander Aristarkhov
Filed: 15 May 18